China gets promising early results from Covid-19 trial

Grant Boone
May 27, 2020

The Maryland-based pharma has begun its trial, which will dose some 130 Australian participants with the new inoculation, hoping to see results as early as July and proceed to the second phase. "We're not waiting. We've begun to scale up to make a vaccine that can be deployed", Glenn said.

It comes days after biotechnology company Moderna had said that the preliminary findings of its test for coronavirus vaccine development have shown favourable results.

"To that end, we have already been manufacturing the material that the clinical grade that you need to use in humans".

Novavax stock was up 13% Tuesday after the company initiated testing of its coronavirus vaccine candidate in people.

The Thai vaccine is being developed by the National Vaccine Institute, the Department of Medical Science and Chulalongkorn University's vaccine research center.

Mr Gates said as of April 9, 115 different COVID-19 potential vaccines were being developed globally.

"Our dream is that low-and middle-income countries should not stay a buyer for our whole lives", he said.

The trial is being supported by the recently announced funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI), an innovative partnership between public, private, philanthropic, and civil society organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics.

Zlatan Ibrahimovic suffers calf injury
The actual nature of the injury is a muscular one in the calf, which occurred when the Swede attempted a shot in training. FIGC has already suspended all its competitions, including Serie A, until June 14 amid the global COVID-19 pandemic.

Over 120 vaccines have been proposed across the world including in India.

How it works: "Novavax used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory", AP reports.

"This means that the animals are protected from the disease and they are not shedding much of the virus to others", explained Gerdts.

They said further research will be needed before this trial vaccine becomes available to all.

These are the body's "humoral response", which is the part of the immune system that produces antibodies to fight infection, and the "cell-mediated" arm, which depends on a group of T cells to fight the virus, the scientists said.

With Novavax shares at the highest in over a week, B Riley FBR's Mayank Mamtani said the stock could return to its May 15 record high, the analyst recommended buying shares ahead of the July results.

Along with moving through the trials, Novavax is also building manufacturing capabilities for the vaccine for quick distribution if it proves successful, the company's research chief Gregory Glenn said during a briefing.

The company added: "AstraZeneca recognizes the heightened risks and uncertainties from the impact of COVID-19".

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER